CHRISTOPHER F NICODEMUS, M.D.
Osteopathic Medicine in Wellesley, MA
License number
Massachusetts 56462
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
2
Unither 15Walnut St, Wellesley, MA 02481
8Th St SUITE 706, Boston, MA 02129
8Th St SUITE 706, Boston, MA 02129
Phone
(781) 416-1506
Personal information
See more information about CHRISTOPHER F NICODEMUS at radaris.comName
Address
Phone
197 8Th St APT 706, Charlestown, MA 02129
197 8Th St #706, Charlestown, MA 02129
Professional information
Chairman And Chief Scientific Officer At Advanced Immune Therapeutics, Inc Principal At Ait Strategies
Location:
Greater Boston Area
Industry:
Biotechnology
Experience:
Advanced Immune Therapeutics, Inc (Biotechnology industry): Chairman and Chief Scientific Officer, (February 2008-Present) Developing novel therapeutic antibodies for cancer immunotherapy; and exploring methods to enhance bioactivity of cancer immunotherpaeutics.AIT Strate...
Dr. Christopher F Nicodemus, Wellesley Hills MA - MD (Doctor of Medicine)
Specialties:
Internal Medicine, Allergy & Immunology
Address:
15 Walnut St, Wellesley Hills 02481
(781) 416-1506 (Phone)
NICODEMUS, CHRISTOPHER F MD
197 8Th St SUITE 706, Charlestown 02129
(617) 242-2216 (Phone)
(781) 416-1506 (Phone)
NICODEMUS, CHRISTOPHER F MD
197 8Th St SUITE 706, Charlestown 02129
(617) 242-2216 (Phone)
Certifications:
Allergy & Immunology, 1989, Internal Medicine, 1987
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Upstate Medical University/ College of Health Professions
Graduated: 1984
New England Deaconess
Brigham-Women
Harvard Medical School
Upstate Medical University/ College of Health Professions
Graduated: 1984
New England Deaconess
Brigham-Women
Harvard Medical School
Christopher Farley Nicodemus, Wellesley Hills MA
Specialties:
Internal Medicine, Allergy & Immunology
Work:
Unither
15 Walnut St, Wellesley Hills, MA 02481
15 Walnut St, Wellesley Hills, MA 02481
Education:
Upstate Medical University Physical Medicine and Rehabilitation (1984)
Methods For Improving The Bioactivity Of Therapeutic Ige Antibodies For The Treatment Of Disease
US Patent:
2011025, Oct 20, 2011
Filed:
Oct 7, 2010
Appl. No.:
12/900251
Inventors:
Birgit C. Schultes - Arlington MA, US
Christopher F. Nicodemus - Charlestown MA, US
Christopher F. Nicodemus - Charlestown MA, US
International Classification:
A61K 39/395, A61P 35/00, A61P 37/06, A61P 37/04
US Classification:
4241331, 4241301, 4241411, 4241551, 4241421
Abstract:
The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.
Methods For Improving The Bioactivity Of Therapeutic Ige Antibodies For The Treatment Of Disease
US Patent:
2013005, Mar 7, 2013
Filed:
Apr 26, 2012
Appl. No.:
13/456492
Inventors:
Birgit C. Schultes - Arlington MA, US
Christopher F. Nicodemus - Charlestown MA, US
Christopher F. Nicodemus - Charlestown MA, US
International Classification:
A61K 39/395, A61P 35/00, A61P 37/02, A61P 37/08
US Classification:
4241331, 4241301, 4241411, 4241421
Abstract:
The invention provides a method for increasing the bioactivity (e.g. the biosafety and efficacy) of a therapeutic IgE antibody of the invention in the treatment of a patient. Methods of the invention include: i) administering to the patient a therapeutic IgE antibody in combination with at least one bioactivity-enhancing agent, ii) strategic treatment regimens and protocols for the dosing and administration of a therapeutic IgE antibody of the invention, and iii) the use of a therapeutic IgE antibody having a variable region comprising at least one antigen binding region specific for binding an epitope of an antigen wherein the epitope is not highly repetitive or is non-repetitive.
Combination Therapy For Treating Disease
US Patent:
2008031, Dec 18, 2008
Filed:
Oct 31, 2007
Appl. No.:
11/981713
Inventors:
Birgit C. Schultes - Arlington MA, US
Christopher F. Nicodemus - Charlestown MA, US
Antoine A. Noujaim - Edmonton, CA
Ragupathy Madiyalakan - Edmonton, CA
Christopher F. Nicodemus - Charlestown MA, US
Antoine A. Noujaim - Edmonton, CA
Ragupathy Madiyalakan - Edmonton, CA
Assignee:
AltaRex Medical Corp. - Edmonton
International Classification:
A61K 39/395, A61P 35/00
US Classification:
4241551
Abstract:
Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.
Ige Antibodies For The Treatment Of Cancer
US Patent:
2011009, Apr 21, 2011
Filed:
Oct 7, 2010
Appl. No.:
12/900256
Inventors:
MANUEL L. PENICHET - LOS ANGELES CA, US
BIRGIT C. SCHULTES - ARLINGTON MA, US
CHRISTOPHER F. NICODEMUS - CHARLESTOWN MA, US
TRACY R. DANIELS - WOODLAND HILLS CA, US
GUSTAVO HELGUERA - LONG BEACH CA, US
JOSE A. RODRIGUEZ - PARAMOUNT CA, US
BIRGIT C. SCHULTES - ARLINGTON MA, US
CHRISTOPHER F. NICODEMUS - CHARLESTOWN MA, US
TRACY R. DANIELS - WOODLAND HILLS CA, US
GUSTAVO HELGUERA - LONG BEACH CA, US
JOSE A. RODRIGUEZ - PARAMOUNT CA, US
International Classification:
A61K 39/395, A61P 35/00, C07K 16/18
US Classification:
4241391, 4241551, 4241561, 5303873, 5303879, 53038815, 5303888
Abstract:
The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).
Ige Antibodies For The Treatment Of Cancer
US Patent:
2013002, Jan 24, 2013
Filed:
Feb 14, 2012
Appl. No.:
13/372557
Inventors:
MANUEL L. PENICHET - LOS ANGELES CA, US
BIRGIT C. SCHULTES - ARLINGTON MA, US
CHRISTOPHER F. NICODEMUS - CHARLESTOWN MA, US
TRACY R. DANIELS - WOODLAND HILLS CA, US
GUSTAVO HELGUERA - LONG BEACH CA, US
JOSE A. RODRIGUEZ - PARAMOUNT CA, US
BIRGIT C. SCHULTES - ARLINGTON MA, US
CHRISTOPHER F. NICODEMUS - CHARLESTOWN MA, US
TRACY R. DANIELS - WOODLAND HILLS CA, US
GUSTAVO HELGUERA - LONG BEACH CA, US
JOSE A. RODRIGUEZ - PARAMOUNT CA, US
International Classification:
C07K 16/18, C07K 19/00, A61P 37/04, A61K 39/395
US Classification:
4241561, 5303888, 5303873, 53038815, 53038885, 5303879, 4241551, 5303911
Abstract:
The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).
Combination Therapy For Treating Disease
US Patent:
8038994, Oct 18, 2011
Filed:
Apr 26, 2004
Appl. No.:
10/831886
Inventors:
Birgit C. Schultes - Arlington MA, US
Christopher F. Nicodemus - Charlestown MA, US
Antoine A. Noujaim - Edmonton, CA
Ragupathy Madiyalakan - Edmonton, CA
Christopher F. Nicodemus - Charlestown MA, US
Antoine A. Noujaim - Edmonton, CA
Ragupathy Madiyalakan - Edmonton, CA
Assignee:
Quest Pharmatech Inc.
International Classification:
A61K 39/395
US Classification:
4241381, 4241411, 4241561
Abstract:
Disclosed are methods for treating cancer comprising administering a xenotypic antibody and a chemotherapeutic drug to a patient suffering from cancer. Also disclosed is a method for inducing a host immune response in a patient against a multi-epitopic in vivo tumor antigen present in the host serum, which antigen does not elicit an effective host immune response, comprising administering to the patient a chemotherapeutic drug and a composition comprising a binding agent that specifically binds to a first epitope on the antigen and allowing the binding agent to form a binding agent/antigen pair, wherein an effective host immune response is elicited against a second epitope on the antigen.
Therapeutic Compositions That Alter The Immune Response
US Patent:
2005003, Feb 10, 2005
Filed:
Mar 8, 2002
Appl. No.:
10/472167
Inventors:
Christopher Nicodemus - Charlestown MA, US
Birgit Schultes - Arlington MA, US
Birgit Schultes - Arlington MA, US
International Classification:
A61K039/395
US Classification:
424155100
Abstract:
The invention is therapeutic methods and compositions that alter the immunogenicity of the host.